Next 10 |
2024-03-21 03:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting PR Newswire Investigator-Sponsored Phase 2 Study Demonstrat...
2024-03-10 03:56:46 ET Summary Third Point's portfolio is still top-heavy, with 10 stocks making up 70% of its AUM. The fund made a large trade by purchasing shares of Verizon and closing out its T-Mobile position. Third Point reduced its positions in Uber, Taiwan Semiconducto...
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer PR Newswire Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif. ...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
2024-03-05 22:43:45 ET Summary Dan Loeb's 13F portfolio value increased to $6.64B this quarter, with the top three holdings accounting for ~37% of the portfolio. Third Point returned 3.4% in 2023 compared to 26.3% for the S&P 500 Index. New stakes include Fleetcor Tech, Ve...
BioMarin Scheduled to Participate in March Investor Conferences PR Newswire - Cowen 44 th Annual Healthcare Conference on March 5 - Leerink Partners Global Biopharma Conference on March 11 - ...
2024-02-29 11:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-23 13:30:03 ET Cantor Fitzgerald analyst issues UNDERPERFORM recommendation for BMRN on February 23, 2024 01:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $91.97 at issue of the analyst recommendation. The overall analyst cons...
2024-02-22 21:08:06 ET BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Conference Call February 22, 2024, 04:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Henry Fuchs - Presi...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
Dennis Slamon, Board Member at Biomarin Pharmaceutical (NASDAQ:BMRN), reported a large exercise of company stock options on March 20, according to ...
2024-03-21 03:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting PR Newswire Investigator-Sponsored Phase 2 Study Demonstrat...